Stocks and Investing Stocks and Investing
Wed, January 19, 2022
Tue, January 18, 2022

Christopher Raymond Reiterated (ABBV) at Buy and Held Target at $160 on, Jan 18th, 2022


Published on 2024-10-27 19:18:29 - WOPRAI, Christopher Raymond
  Print publication without navigation


Christopher Raymond of Piper Sandler, Reiterated "AbbVie Inc." (ABBV) at Buy and Held Target at $160 on, Jan 18th, 2022.

Christopher has made no other calls on ABBV in the last 4 months.



There are 12 other peers that have a rating on ABBV. Out of the 12 peers that are also analyzing ABBV, 3 agree with Christopher's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Chris Shibutani of "Goldman Sachs" Initiated at Hold and Held Target at $113 on, Friday, December 17th, 2021
  • Luisa Hector of "Berenberg" Maintained at Hold and Held Target at $105 on, Wednesday, November 24th, 2021
  • Carter Gould of "Barclays" Maintained at Hold with Increased Target to $118 on, Monday, November 1st, 2021


These are the ratings of the 9 analyists that currently disagree with Christopher


  • Charles Pitman of "Redburn Partners" Initiated at Strong Buy on, Thursday, January 13th, 2022
  • Gary Nachman of "BMO Capital" Maintained at Buy with Increased Target to $153 on, Wednesday, January 12th, 2022
  • Vamil Divan of "Mizuho" Maintained at Strong Buy with Increased Target to $154 on, Wednesday, January 5th, 2022
  • Aaron Gal of "Bernstein" Maintained at Buy with Increased Target to $155 on, Monday, January 3rd, 2022
  • Mohit Bansal of "Wells Fargo" Initiated at Buy and Held Target at $165 on, Thursday, December 9th, 2021
  • Navin Jacob of "UBS" Maintained at Strong Buy with Increased Target to $129 on, Monday, November 29th, 2021
  • Justin Smith of "Societe Generale" Upgraded from Hold to Strong Buy and Held Target at $172 on, Tuesday, November 23rd, 2021
  • Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $124 on, Monday, November 1st, 2021
  • Geoffrey Porges of "SVB Leerink" Maintained at Buy with Decreased Target to $135 on, Monday, November 1st, 2021

Contributing Sources